Budesonide: Brands, Price & Uses in Bangladesh

Budesonide is a corticosteroid used in different formulations for several distinct conditions:

• Asthma (inhaled form): FDA-approved for maintenance treatment of asthma as prophylactic (preventive) therapy in adults and children. It is not a bronchodilator and must not be used to relieve an acute asthma attack.
• Allergic rhinitis (intranasal form): FDA-approved for relief of symptoms of seasonal and perennial allergic rhinitis (nasal congestion, sneezing, runny nose, itching) in adults and children.
• Crohn's disease (oral controlled-ileal-release capsule): Guideline-supported and FDA-approved for induction of remission in mild-to-moderate active Crohn's disease involving the ileum and/or ascending colon, and for maintenance of remission for up to 3 months.
• Ulcerative colitis (oral extended-release tablet or rectal foam): FDA-approved for induction of remission in patients with active mild-to-moderate ulcerative colitis.
• Microscopic colitis (off-label/guideline-supported use): Commonly used, based on clinical guidelines, for induction and maintenance of remission in collagenous and lymphocytic colitis, though this is not an FDA-labeled indication in all formulations.

The specific formulation (inhaler, nebulizer suspension, nasal spray, oral capsule/tablet, or rectal foam) determines which indication applies; formulations are not interchangeable.

Dosage of Budesonide is specific to the formulation and indication; dose from one formulation cannot be substituted for another.

Administration: Inhaled forms should be used at regular intervals, not as needed for acute symptoms; patients should rinse the mouth with water after each inhalation to reduce the risk of oral candidiasis. Nasal spray should be shaken (if suspension) and sprayed into each nostril while breathing gently inward, avoiding the nasal septum. Oral capsules/tablets should be swallowed whole with water and not crushed, chewed, or opened, as this destroys the controlled-release mechanism. Rectal foam is administered per the product's applicator instructions, generally at bedtime and after a bowel movement when possible.

No renal dose adjustment is well established. In hepatic impairment, systemic exposure to Budesonide may increase due to reduced first-pass metabolism; dose reduction and close monitoring are recommended in moderate-to-severe hepatic impairment.

Side effects of Budesonide vary by formulation:

• Inhaled (asthma): oral candidiasis (thrush — reduce risk by rinsing mouth after use), hoarseness/dysphonia, throat irritation, cough. Rarely, paradoxical bronchospasm.
• Intranasal (allergic rhinitis): nasal irritation and dryness, epistaxis (nosebleed), headache, sore throat, and rarely nasal septal perforation with prolonged use.
• Oral (Crohn's disease/ulcerative colitis): headache, nausea, abdominal pain, respiratory infection symptoms, and adrenal suppression — this risk is lower than with conventional systemic corticosteroids owing to the gut-targeted release design, but is not eliminated, particularly with higher doses or prolonged courses. Cushingoid features (weight gain, moon face, striae) can occur with prolonged or high-dose use of any formulation.
• All forms (systemic, uncommon): growth suppression in children with long-term use, increased susceptibility to infection, and rarely, effects on bone mineral density with long-term therapy.